Financial Survey: Tandem Diabetes Care (NASDAQ:TNDM) versus Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ)

Tandem Diabetes Care (NASDAQ:TNDMGet Free Report) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQGet Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, risk and earnings.

Risk and Volatility

Tandem Diabetes Care has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, meaning that its share price is 91% less volatile than the S&P 500.

Profitability

This table compares Tandem Diabetes Care and Health Sciences Acquisitions Co. 2’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tandem Diabetes Care -18.37% -34.38% -10.91%
Health Sciences Acquisitions Co. 2 N/A N/A -2.38%

Insider and Institutional Ownership

89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 2.2% of Tandem Diabetes Care shares are owned by insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Tandem Diabetes Care and Health Sciences Acquisitions Co. 2’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tandem Diabetes Care $747.72 million 3.70 -$222.61 million ($2.17) -19.74
Health Sciences Acquisitions Co. 2 N/A N/A -$380,000.00 N/A N/A

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Tandem Diabetes Care.

Analyst Ratings

This is a summary of current recommendations and price targets for Tandem Diabetes Care and Health Sciences Acquisitions Co. 2, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tandem Diabetes Care 0 1 12 0 2.92
Health Sciences Acquisitions Co. 2 0 0 0 0 N/A

Tandem Diabetes Care presently has a consensus target price of $51.25, suggesting a potential upside of 19.63%. Given Tandem Diabetes Care’s higher probable upside, research analysts clearly believe Tandem Diabetes Care is more favorable than Health Sciences Acquisitions Co. 2.

Summary

Health Sciences Acquisitions Co. 2 beats Tandem Diabetes Care on 6 of the 10 factors compared between the two stocks.

About Tandem Diabetes Care

(Get Free Report)

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

About Health Sciences Acquisitions Co. 2

(Get Free Report)

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.